secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001193125-24-006600
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron partners with CrossLink to add ~650 sales reps for ZYNRELEF through 2028
------------------------------------------------------------------------------

- CrossLink adds at least 325 sales reps by July 2024 and 650 by Jan 2025.
- Fixed-fee per vial compensation based on growth over baseline period.
- Up to 1,666,670 shares of common stock and $5M in milestone payments.
- Five-year term ending Dec 2028, renewable annually.
- Partnership targets orthopedic indications; initial regional rollout expands nationally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/0001193125-24-006600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/d636605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-006600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer